- Home
- Publications
- Publication Search
- Publication Details
Title
The Multifaceted Biology of PCSK9
Authors
Keywords
-
Journal
ENDOCRINE REVIEWS
Volume -, Issue -, Pages -
Publisher
The Endocrine Society
Online
2021-10-10
DOI
10.1210/endrev/bnab035
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The State of the Problem of Achieving Extremely Low LDL Levels
- (2021) Victoria Korneva et al. CURRENT PHARMACEUTICAL DESIGN
- Human Molecular Genetics and Genomics — Important Advances and Exciting Possibilities
- (2021) Francis S. Collins et al. NEW ENGLAND JOURNAL OF MEDICINE
- Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity
- (2021) Cyrielle Fougeroux et al. Nature Communications
- Lipid Lowering Drugs: Present Status and Future Developments
- (2021) Massimiliano Ruscica et al. Current Atherosclerosis Reports
- Patterns and tempo of PCSK9 pseudogenizations suggest an ancient divergence in mammalian cholesterol homeostasis mechanisms
- (2021) Barbara van Asch et al. GENETICA
- Humanized Mice as a Tool to Study Sepsis—More Than Meets the Eye
- (2021) Krzysztof Laudanski INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Inclisiran
- (2021) Vijay Nambi et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Potentiating CD8+ T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling
- (2021) Juanjuan Yuan et al. Protein & Cell
- A Critical Review of the Efficacy and Safety of Inclisiran
- (2021) Jennifer Hardy et al. American Journal of Cardiovascular Drugs
- Effects of proprotein convertase subtilisin kexin type 9 modulation in human pancreatic beta cells function
- (2021) Stéphane Ramin-Mangata et al. ATHEROSCLEROSIS
- Development of humanized mouse with patient‐derived xenografts for cancer immunotherapy studies: a comprehensive review
- (2021) Ke‐Tao Jin et al. CANCER SCIENCE
- Novel CRISPR–Cas Systems: An Updated Review of the Current Achievements, Applications, and Future Research Perspectives
- (2021) Sweta Nidhi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates
- (2021) Kiran Musunuru et al. NATURE
- Adoption of PCSK9 Inhibitors Among Patients With Atherosclerotic Disease
- (2021) Elias J. Dayoub et al. Journal of the American Heart Association
- Rapid Decline of Serum Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy
- (2021) Jonathan Grimm et al. Journal of Clinical Medicine
- The emerging landscape of peptide-based inhibitors of PCSK9
- (2021) Benjamin J. Tombling et al. ATHEROSCLEROSIS
- Trends in lipid-modifying agent use in 83 countries
- (2021) Joseph E. Blais et al. ATHEROSCLEROSIS
- Substantial PCSK9 inactivation in β-cells does not modify glucose homeostasis or insulin secretion in mice
- (2021) Marie-Line Peyot et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Proprotein convertase subtilisin/kexin type 9 (PCSK9): A potential multifaceted player in cancer
- (2021) Anindita Bhattacharya et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- The size of apolipoprotein (a) is an independent determinant of the reduction in lipoprotein (a) induced by PCSK9 inhibitors
- (2021) Valentin Blanchard et al. CARDIOVASCULAR RESEARCH
- Asialoglycoprotein receptor 1 is a novel PCSK9-independent ligand of liver LDLR cleaved by Furin
- (2021) Delia Susan-Resiga et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Proprotein convertase subtilisin/kexin type 9 regulates the production of acute‐phase reactants from the liver
- (2021) Dafne Jacome Sanz et al. LIVER INTERNATIONAL
- Influence of cholesterol on cancer progression and therapy
- (2021) Shyamananda Singh Mayengbam et al. Translational Oncology
- How Do Enveloped Viruses Exploit the Secretory Proprotein Convertases to Regulate Infectivity and Spread?
- (2021) Nabil G. Seidah et al. Viruses-Basel
- Three Musketeers for Lowering Cholesterol: Statins, Ezetimibe and Evolocumab
- (2020) Qian Xu et al. CURRENT MEDICINAL CHEMISTRY
- The haemochromatosis gene Hfe and Kupffer cells control LDL cholesterol homeostasis and impact on atherosclerosis development
- (2020) Egon Demetz et al. EUROPEAN HEART JOURNAL
- CRISPR-Cas12a delivery by DNA-mediated bioresponsive editing for cholesterol regulation
- (2020) Wujin Sun et al. Science Advances
- Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction
- (2020) Stephen D. Wiviott et al. JAMA Cardiology
- Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis
- (2020) Paul Guedeney et al. European Heart Journal-Cardiovascular Pharmacotherapy
- Circulating Rather Than Intestinal PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Regulates Postprandial Lipemia in Mice
- (2020) Damien Garçon et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19
- (2020) Xiao-Jing Zhang et al. Cell Metabolism
- Proprotein Convertase Subtilisin/Kexin Type 9 Loss-of-Function Is Detrimental to the Juvenile Host With Septic Shock
- (2020) Mihir R. Atreya et al. CRITICAL CARE MEDICINE
- New Pharmacological Approaches to Target PCSK9
- (2020) Alberico L. Catapano et al. Current Atherosclerosis Reports
- PCSK9 Inhibitors and Ezetimibe Monotherapy in Patients Not Receiving Statins: A Meta-Analysis of Randomized Trials
- (2020) Benjamin Benhuri et al. Current Vascular Pharmacology
- Transcription factors activated through RIP (regulated intramembrane proteolysis) and RAT (regulated alternative translocation)
- (2020) Jin Ye JOURNAL OF BIOLOGICAL CHEMISTRY
- Prevention of endothelial dysfunction and thrombotic events in COVID-19 patients with familial hypercholesterolemia
- (2020) Alpo Vuorio et al. Journal of Clinical Lipidology
- PCSK9 is associated with mortality in patients with septic shock: data from the ALBIOS study
- (2020) A. Vecchié et al. JOURNAL OF INTERNAL MEDICINE
- Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing
- (2020) Tuo Wei et al. Nature Communications
- A decade of immune-checkpoint inhibitors in cancer therapy
- (2020) Caroline Robert Nature Communications
- Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy
- (2020) Prakash Deedwania et al. JAMA Cardiology
- Plasma PCSK9 levels and sepsis severity: an early assessment in the emergency department
- (2020) Francesca Innocenti et al. CLINICAL AND EXPERIMENTAL MEDICINE
- Dengue virus induces PCSK9 expression to alter antiviral responses and disease outcomes
- (2020) Esther Shuyi Gan et al. JOURNAL OF CLINICAL INVESTIGATION
- Global view of human protein glycosylation pathways and functions
- (2020) Katrine T. Schjoldager et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Statin use is associated with lower disease severity in COVID-19 infection
- (2020) Wilnard Y. T. Tan et al. Scientific Reports
- PCSK9: A Potential Therapeutic Target for Sepsis
- (2020) Yuan Yuan et al. Journal of Immunology Research
- The loss-of-function PCSK9Q152H variant increases ER chaperones GRP78 and GRP94 and protects against liver injury
- (2020) Paul F. Lebeau et al. JOURNAL OF CLINICAL INVESTIGATION
- PCSK9 inhibitors for COVID‐19: an opportunity to enhance the antiviral action of interferon in patients with hypercholesterolaemia
- (2020) A. Vuorio et al. JOURNAL OF INTERNAL MEDICINE
- PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
- (2020) Julius L. Katzmann et al. Frontiers in Physiology
- Novel strategies to target PCSK9: beyond monoclonal antibodies
- (2019) Nabil G Seidah et al. CARDIOVASCULAR RESEARCH
- Molecular regulation of plasma lipid levels during systemic inflammation and sepsis
- (2019) Mark Trinder et al. CURRENT OPINION IN LIPIDOLOGY
- The Elusive Inhibitory Function of the Acidic N-Terminal Segment of the Prodomain of PCSK9: The Plot Thickens
- (2019) Nabil G. Seidah JOURNAL OF MOLECULAR BIOLOGY
- Patients with Recent Acute Coronary Syndrome and Polyvascular Disease Derive Large Absolute Benefit from Alirocumab: ODYSSEY OUTCOMES Trial
- (2019) J. Wouter Jukema et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia
- (2019) Henry N. Ginsberg et al. CARDIOVASCULAR DRUGS AND THERAPY
- 2018 Cholesterol Clinical Practice Guidelines: Synopsis of the 2018 American Heart Association/American College of Cardiology/Multisociety Cholesterol Guideline*
- (2019) Scott M. Grundy et al. ANNALS OF INTERNAL MEDICINE
- The immune functions of PCSK9: Local and systemic perspectives
- (2019) Xing Liu et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Reduced plasma PCSK 9 response in patients with bacteraemia is associated with mortality
- (2019) Juha Rannikko et al. JOURNAL OF INTERNAL MEDICINE
- Reduced Proprotein convertase subtilisin/kexin 9 (PCSK9) function increases lipoteichoic acid clearance and improves outcomes in Gram positive septic shock patients
- (2019) Alex K. K. Leung et al. Scientific Reports
- Low-density lipoprotein receptor-deficient hepatocytes differentiated from induced pluripotent stem cells allow familial hypercholesterolemia modeling, CRISPR/Cas-mediated genetic correction, and productive hepatitis C virus infection
- (2019) Jérôme Caron et al. Stem Cell Research & Therapy
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
- (2019) François Mach et al. EUROPEAN HEART JOURNAL
- Functional analysis of natural PCSK 9 mutants in modern and archaic humans
- (2019) Sepideh Mikaeeli et al. FEBS Journal
- Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor)
- (2019) Ali Ben Djoudi Ouadda et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1
- (2019) Zufeng Ding et al. CARDIOVASCULAR RESEARCH
- Very Low Density Lipoprotein Receptor Sequesters Lipopolysaccharide Into Adipose Tissue During Sepsis
- (2019) Tadanaga Shimada et al. CRITICAL CARE MEDICINE
- PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages
- (2018) Zufeng Ding et al. CARDIOVASCULAR RESEARCH
- The journey towards understanding lipoprotein(a) and cardiovascular disease risk
- (2018) Michael B. Boffa et al. CURRENT OPINION IN LIPIDOLOGY
- Proprotein convertase subtilisin/kexin type 9 inhibits interferon β expression through interacting with ATF-2
- (2018) Zhubing Li et al. FEBS LETTERS
- Unconventional protein secretion – new insights into the pathogenesis and therapeutic targets of human diseases
- (2018) Jiyoon Kim et al. JOURNAL OF CELL SCIENCE
- How many human proteoforms are there?
- (2018) Ruedi Aebersold et al. Nature Chemical Biology
- New Sequencing technologies help revealing unexpected mutations in Autosomal Dominant Hypercholesterolemia
- (2018) Sandy Elbitar et al. Scientific Reports
- A single domain antibody against the Cys- and His-rich domain of PCSK9 and evolocumab exhibit different inhibition mechanisms in humanized PCSK9 mice
- (2018) Rachid Essalmani et al. BIOLOGICAL CHEMISTRY
- Whole-Gene Duplication of PCSK9 as a Novel Genetic Mechanism for Severe Familial Hypercholesterolemia
- (2018) Michael A. Iacocca et al. CANADIAN JOURNAL OF CARDIOLOGY
- A Mendelian randomization study of the effects of blood lipids on breast cancer risk
- (2018) Christoph Nowak et al. Nature Communications
- Low-density lipoprotein (LDL)-dependent uptake of Gram-positive lipoteichoic acid and Gram-negative lipopolysaccharide occurs through LDL receptor
- (2018) Peter M. Grin et al. Scientific Reports
- Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C
- (2018) Roberta D'Ambrosio et al. JOURNAL OF HEPATOLOGY
- The interrelations between PCSK9 metabolism and cholesterol synthesis and absorption
- (2018) Günther Silbernagel et al. JOURNAL OF LIPID RESEARCH
- Cell-associated heparin-like molecules modulate the ability of LDL to regulate PCSK9 uptake
- (2018) Adri M. Galvan et al. JOURNAL OF LIPID RESEARCH
- Single-cell transcriptomics of 20 mouse organs creates a Tabula Muris
- (2018) et al. NATURE
- In utero CRISPR-mediated therapeutic editing of metabolic genes
- (2018) Avery C. Rossidis et al. NATURE MEDICINE
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
- (2018) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Plaque burden influences accurate classification of fibrous cap atheroma by in vivo optical coherence tomography in a porcine model of advanced coronary atherosclerosis
- (2018) Christian B. Poulsen et al. EuroIntervention
- Impact of PCSK9 loss-of-function genotype on 1-year mortality and recurrent infection in sepsis survivors
- (2018) Kelly Roveran Genga et al. EBioMedicine
- The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice
- (2017) Christine Landlinger et al. EUROPEAN HEART JOURNAL
- Can iPCSK9-induced hypocholesterolemia starve cancer cells?
- (2017) Anne Gangloff et al. Journal of Clinical Lipidology
- Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia
- (2017) John J.P. Kastelein et al. Journal of Clinical Lipidology
- Insights into a PCSK9 structural groove: a harbinger of new drugs to reduce LDL-cholesterol
- (2017) Nabil G Seidah NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
- (2017) Kevin Fitzgerald et al. NEW ENGLAND JOURNAL OF MEDICINE
- Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes
- (2017) Michael Tanowitz et al. NUCLEIC ACIDS RESEARCH
- Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9
- (2017) Rocco Romagnuolo et al. PLoS One
- Insights into a PCSK9 structural groove: a harbinger of new drugs to reduce LDL-cholesterol
- (2017) Nabil G Seidah NATURE STRUCTURAL & MOLECULAR BIOLOGY
- MAIT cells launch a rapid, robust and distinct hyperinflammatory response to bacterial superantigens and quickly acquire an anergic phenotype that impedes their cognate antimicrobial function: Defining a novel mechanism of superantigen-induced immunopathology and immunosuppression
- (2017) Christopher R. Shaler et al. PLOS BIOLOGY
- Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
- (2017) Marc S Sabatine et al. Lancet Diabetes & Endocrinology
- GALNT6 Stabilizes GRP78 Protein by O-glycosylation and Enhances its Activity to Suppress Apoptosis Under Stress Condition
- (2017) Jiaying Lin et al. NEOPLASIA
- Treatment-Induced Viral Cure of Hepatitis C Virus-Infected Patients Involves a Dynamic Interplay among three Important Molecular Players in Lipid Homeostasis: Circulating microRNA (miR)-24, miR-223, and Proprotein Convertase Subtilisin/Kexin Type 9
- (2017) Anastasia Hyrina et al. EBioMedicine
- Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor)
- (2017) Aurélie Thedrez et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus
- (2017) Robert P. Giugliano et al. CIRCULATION
- A Therapeutic Peptide Vaccine Against PCSK9
- (2017) Yajie Pan et al. Scientific Reports
- Immune Blockade Inhibition in Breast Cancer
- (2016) IOANNIS A VOUTSADAKIS ANTICANCER RESEARCH
- Immune checkpoint inhibitors for cancer treatment
- (2016) Junsik Park et al. ARCHIVES OF PHARMACAL RESEARCH
- Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia
- (2016) Ioanna Gouni-Berthold et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Role of lipoproteins and proprotein convertase subtilisin/kexin type 9 in endotoxin clearance in sepsis
- (2016) Keith R. Walley Current Opinion in Critical Care
- New developments in proprotein convertase subtilisin–kexin 9ʼs biology and clinical implications
- (2016) Nabil G. Seidah CURRENT OPINION IN LIPIDOLOGY
- The effect of fluvastatin on cardiac fibrosis and angiotensin-converting enzyme-2 expression in glucose-controlled diabetic rat hearts
- (2016) Young Hee Shin et al. HEART AND VESSELS
- The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
- (2016) Mervyn Singer et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Site-1 protease is required for the generation of soluble (pro)renin receptor
- (2016) Tsutomu Nakagawa et al. JOURNAL OF BIOCHEMISTRY
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation
- (2016) Elodie Weider et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The Proprotein Convertase Subtilisin/Kexin Type 9-resistant R410S Low Density Lipoprotein Receptor Mutation
- (2016) Delia Susan-Resiga et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- GRP78 Interacting Partner Bag5 Responds to ER Stress and Protects Cardiomyocytes From ER Stress-Induced Apoptosis
- (2016) Manish K. Gupta et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia
- (2016) Matthew K. Ito et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Increased Plasma PCSK9 Levels Are Associated with Reduced Endotoxin Clearance and the Development of Acute Organ Failures during Sepsis
- (2016) John H. Boyd et al. Journal of Innate Immunity
- Differential Expression of PCSK9 Modulates Infection, Inflammation, and Coagulation in a Murine Model of Sepsis
- (2016) Dhruva J. Dwivedi et al. SHOCK
- Relationship Between Low‐Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid‐Lowering Strategies
- (2016) Jacques Rey et al. Journal of the American Heart Association
- Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain
- (2016) Steve Poirier et al. PLoS One
- PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse LiverSignificance
- (2015) Annie Demers et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: Role of epigenetic histone modifications
- (2015) Kulbhushan Tikoo et al. BIOCHEMICAL PHARMACOLOGY
- A Single Kinase Generates the Majority of the Secreted Phosphoproteome
- (2015) Vincent S. Tagliabracci et al. CELL
- Role of Ezetimibe in Lipid-Lowering and Cardiovascular Disease Prevention
- (2015) Bryan A. Smith et al. Current Atherosclerosis Reports
- Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other
- (2015) Chutikarn Butkinaree et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor
- (2015) Rocco Romagnuolo et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Role of the unfolded protein response, GRP78 and GRP94 in organ homeostasis
- (2015) Genyuan Zhu et al. JOURNAL OF CELLULAR PHYSIOLOGY
- PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: Evidence for genotype-specific regulation of lipoprotein metabolism
- (2015) Simon H. Bridge et al. JOURNAL OF HEPATOLOGY
- The future of murine sepsis and trauma research models
- (2015) Philip A. Efron et al. JOURNAL OF LEUKOCYTE BIOLOGY
- PCSK9 deficiency unmasks a sex- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice
- (2015) Anna Roubtsova et al. JOURNAL OF LIPID RESEARCH
- Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma
- (2015) Fabienne Guillaumond et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A cholesterol-lowering VLP vaccine that targets PCSK9
- (2015) Erin Crossey et al. VACCINE
- GRP94 Regulates Circulating Cholesterol Levels through Blockade of PCSK9-Induced LDLR Degradation
- (2015) Steve Poirier et al. Cell Reports
- A secretory kinase complex regulates extracellular protein phosphorylation
- (2015) Jixin Cui et al. eLife
- Proprotein Convertase Subtilisin/Kexin Type 9 Deficiency Reduces Melanoma Metastasis in Liver
- (2015) Xiaowei Sun et al. NEOPLASIA
- Reduction of Low-Density Lipoprotein Cholesterol by Monoclonal Antibody Inhibition of PCSK9
- (2014) Evan A. Stein et al. Annual Review of Medicine
- Nikolai N. Anitschkow and the lipid hypothesis of atherosclerosis
- (2014) L. Maximilian Buja CARDIOVASCULAR PATHOLOGY
- Induction of Atherosclerosis in Mice and Hamsters Without Germline Genetic Engineering
- (2014) Martin Mæng Bjørklund et al. CIRCULATION RESEARCH
- PCSK9
- (2014) Nabil G. Seidah et al. CIRCULATION RESEARCH
- Permanent Alteration of PCSK9 With In Vivo CRISPR-Cas9 Genome Editing
- (2014) Qiurong Ding et al. CIRCULATION RESEARCH
- Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial
- (2014) Eli M. Roth et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Isolation and characterization of the circulating truncated form of PCSK9
- (2014) Bomie Han et al. JOURNAL OF LIPID RESEARCH
- Anti-PCSK9 Monotherapy for Hypercholesterolemia
- (2014) Michael J. Koren et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- PCSK9 is a critical regulator of the innate immune response and septic shock outcome
- (2014) K. R. Walley et al. Science Translational Medicine
- The Multifaceted Proprotein Convertases: Their Unique, Redundant, Complementary, and Opposite Functions
- (2013) Nabil G. Seidah et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Bile acid and sterol metabolism with combined HMG-CoA reductase and PCSK9 suppression
- (2013) Rex A. Parker et al. JOURNAL OF LIPID RESEARCH
- An Antibody against the C-Terminal Domain of PCSK9 Lowers LDL Cholesterol Levels In Vivo
- (2013) Felix Schiele et al. JOURNAL OF MOLECULAR BIOLOGY
- The global distribution and burden of dengue
- (2013) Samir Bhatt et al. NATURE
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)
- (2013) Maryssa Canuel et al. PLoS One
- PCSK9 Prosegment Chimera as Novel Inhibitors of LDLR Degradation
- (2013) Yascara Grisel Luna Saavedra et al. PLoS One
- Hepatitis C Virus, Cholesterol and Lipoproteins — Impact for the Viral Life Cycle and Pathogenesis of Liver Disease
- (2013) Daniel Felmlee et al. Viruses-Basel
- The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics
- (2013) Pedro M. R. Cruz et al. Frontiers in Pharmacology
- How the Prohormone Theory Solved Two Important Controversies in Hormonal and Neural Peptide Biosynthesis
- (2013) Michel Chrétien Frontiers in Endocrinology
- Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia
- (2012) Marianne Abifadel et al. ATHEROSCLEROSIS
- Site-specific protein O-glycosylation modulates proprotein processing — Deciphering specific functions of the large polypeptide GalNAc-transferase gene family
- (2012) Katrine T.-B.G. Schjoldager et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- Increased Expression of LDL Receptor-Related Protein 1 during Human Cytomegalovirus Infection Reduces Virion Cholesterol and Infectivity
- (2012) Nicole Gudleski-O'Regan et al. Cell Host & Microbe
- Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice
- (2012) Maxime Denis et al. CIRCULATION
- SKI-1 and Furin Generate Multiple RGMa Fragments that Regulate Axonal Growth
- (2012) Nardos G. Tassew et al. DEVELOPMENTAL CELL
- The M2 Module of the Cys-His-rich Domain (CHRD) of PCSK9 Protein Is Needed for the Extracellular Low-density Lipoprotein Receptor (LDLR) Degradation Pathway
- (2012) Yascara Grisel Luna Saavedra et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Loss- and Gain-of-function PCSK9 Variants
- (2012) Suzanne Benjannet et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The biology and therapeutic targeting of the proprotein convertases
- (2012) Nabil G. Seidah et al. NATURE REVIEWS DRUG DISCOVERY
- A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity
- (2012) M. Jinek et al. SCIENCE
- Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue
- (2011) Anna Roubtsova et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Removal of acidic residues of the prodomain of PCSK9 increases its activity towards the LDL receptor
- (2011) Øystein L. Holla et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Rosuvastatin, Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations, and LDL Cholesterol Response: the JUPITER Trial
- (2011) Z. Awan et al. CLINICAL CHEMISTRY
- Novel Loss-of-Function PCSK9 Variant Is Associated with Low Plasma LDL Cholesterol in a French-Canadian Family and with Impaired Processing and Secretion in Cell Culture
- (2011) J. Mayne et al. CLINICAL CHEMISTRY
- Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH
- (2011) Paola Lo Surdo et al. EMBO REPORTS
- Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors
- (2011) Øystein L. Holla et al. JOURNAL OF LIPID RESEARCH
- PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke
- (2011) Estelle Rousselet et al. JOURNAL OF LIPID RESEARCH
- Characterization of a naturally occurring degradation product of the LDL receptor
- (2011) Kristian Tveten et al. MOLECULAR GENETICS AND METABOLISM
- A Key Enzyme in the Biogenesis of Lysosomes Is a Protease That Regulates Cholesterol Metabolism
- (2011) K. Marschner et al. SCIENCE
- Increased Secretion of Lipoproteins in Transgenic Mice Expressing Human D374Y PCSK9 Under Physiological Genetic Control
- (2010) Bronwen Herbert et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- A Proprotein Convertase Subtilisin-like/Kexin Type 9 (PCSK9) C-terminal Domain Antibody Antigen-binding Fragment Inhibits PCSK9 Internalization and Restores Low Density Lipoprotein Uptake
- (2010) Yan G. Ni et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- In VivoEvidence That Furin from Hepatocytes Inactivates PCSK9
- (2010) Rachid Essalmani et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Effects of the Prosegment and pH on the Activity of PCSK9
- (2010) Suzanne Benjannet et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain
- (2010) Mali Liu et al. JOURNAL OF LIPID RESEARCH
- Disrupted recycling of the low density lipoprotein receptor by PCSK9 is not mediated by residues of the cytoplasmic domain
- (2010) Thea Bismo Strøm et al. MOLECULAR GENETICS AND METABOLISM
- A historical perspective on the discovery of statins
- (2010) Akira ENDO PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES
- PCSK9 Dominant Negative Mutant Results in Increased LDL Catabolic Rate and Familial Hypobetalipoproteinemia
- (2009) Bertrand Cariou et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- The LDL Receptor
- (2009) Joseph L. Goldstein et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- PCSK9 is expressed in pancreatic δ-cells and does not alter insulin secretion
- (2009) Cédric Langhi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- The role of resistin as a regulator of inflammation: Implications for various human pathologies
- (2009) Mária Filková et al. CLINICAL IMMUNOLOGY
- PCSK9 impedes hepatitis C virus infectionin vitroand modulates liver CD81 expression
- (2009) Patrick Labonté et al. HEPATOLOGY
- Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease
- (2009) Marianne Abifadel et al. HUMAN MUTATION
- Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality
- (2009) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells
- (2009) Markey C. McNutt et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation
- (2009) Steve Poirier et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Genetic and Metabolic Determinants of Plasma PCSK9 Levels
- (2009) Susan G. Lakoski et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A new method for measurement of total plasma PCSK9: clinical applications
- (2009) Geneviève Dubuc et al. JOURNAL OF LIPID RESEARCH
- A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates
- (2009) J. C. Y. Chan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Degradation of LDLR protein mediated by ‘gain of function’ PCSK9 mutants in normal and ARH cells
- (2008) Tommaso Fasano et al. ATHEROSCLEROSIS
- Plasma PCSK9 Concentrations Correlate with LDL and Total Cholesterol in Diabetic Patients and Are Decreased by Fenofibrate Treatment
- (2008) G. Lambert et al. CLINICAL CHEMISTRY
- Investigations on the evolutionary conservation of PCSK9 reveal a functionally important protrusion
- (2008) Jamie Cameron et al. FEBS Journal
- Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration
- (2008) Ahmed Zaid et al. HEPATOLOGY
- Structural and Biochemical Characterization of the Wild Type PCSK9-EGF(AB) Complex and Natural Familial Hypercholesterolemia Mutants
- (2008) Matthew J. Bottomley et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Annexin A2 Is a C-terminal PCSK9-binding Protein That Regulates Endogenous Low Density Lipoprotein Receptor Levels
- (2008) Gaétan Mayer et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PCSK9: a convertase that coordinates LDL catabolism
- (2008) Jay D. Horton et al. JOURNAL OF LIPID RESEARCH
- Molecular basis for LDL receptor recognition by PCSK9
- (2008) H. J. Kwon et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor
- (2008) D.-W. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A combined treatment of HeLa cells with the farnesyl protein transferase inhibitor L-744,832 and cisplatin significantly increases the therapeutic effect as compared to cisplatin monotherapy
- (2007) Józefa Węsierska-Gądek et al. JOURNAL OF CELLULAR BIOCHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More